戻る
「早戻しボタン」を押すと検索画面に戻ります。 [閉じる]

コーパス検索結果 (１語後でソート)

通し番号をクリックするとPubMedの該当ページを表示します
1 and thereby causes extreme susceptibility to pneumococcal infection.
2 tion is associated with an increased risk of pneumococcal infection.
3 at T cell immunity may be protective against pneumococcal infection.
4 he efficacy of beta-lactams for treatment of pneumococcal infection.
5 ell wall and provides innate defense against pneumococcal infection.
6 en implicated in increased susceptibility to pneumococcal infection.
7 play important roles in host defense against pneumococcal infection.
8  they may be involved at different stages of pneumococcal infection.
9 s neuraminidase (NA) has in priming mice for pneumococcal infection.
10 n-deficient mice were extremely sensitive to pneumococcal infection.
11 trepto-coccus pneumoniae and its role during pneumococcal infection.
12 fort to explore mucosal immunization against pneumococcal infection.
13 y to pneumolysin provides protection against pneumococcal infection.
14 e in adult mice and protect mice from lethal pneumococcal infection.
15 man antibody to PspA could protect mice from pneumococcal infection.
16  to provide optimal protection from virulent pneumococcal infection.
17 ed the role of CD40L in host defense against pneumococcal infection.
18 sodes of otitis media, and 116 deaths due to pneumococcal infection.
19 d do not protect against death from virulent pneumococcal infection.
20 BEAS-2B cell line for studying mechanisms of pneumococcal infection.
21 d elicit protective immune responses against pneumococcal infection.
22 can elicit protective immunity against fatal pneumococcal infection.
23 mplement and macrophages in a mouse model of pneumococcal infection.
24 sufficiency with increased susceptibility to pneumococcal infection.
25 tx3(-/-) mice presented more severe invasive pneumococcal infection.
26 igned to assess the role of PTX3 in invasive pneumococcal infection.
27 inflammation and resistance against invasive pneumococcal infection.
28 s of ZIP8 in macrophage and DC function upon pneumococcal infection.
29 s of natural IgM-mediated protection against pneumococcal infection.
30 peutic tool to protect against ALI caused by pneumococcal infection.
31 and the resulting protection of mice against pneumococcal infection.
32 CD) patients are at high risk of contracting pneumococcal infection.
33 astin (LPL) succumb rapidly to intratracheal pneumococcal infection.
34  this cell type in the immediate response to pneumococcal infection.
35  mutant CRP did not protect mice from lethal pneumococcal infection.
36 lly promotes a high risk of lethal, invasive pneumococcal infection.
37 ed initial protection of mice against lethal pneumococcal infection.
38 ar recruitment and bacterial loads following pneumococcal infection.
39 rways via this integrin at an early stage of pneumococcal infection.
40  genetic risk factors with predisposition to pneumococcal infection.
41 on within lung tissue, but for combating the pneumococcal infection.
42 ciated with differences in susceptibility to pneumococcal infection.
43  eliciting cross-protection immunity against pneumococcal infection.
44  of choice for patients with possible severe pneumococcal infection.
45 n vivo to reduced mouse morbidity from fatal pneumococcal infection.
46 e would become more susceptible to secondary pneumococcal infection.
47 tosis and rescues mice from life-threatening pneumococcal infection.
48  induce a protective immune response against pneumococcal infection.
49 and systemic immunity for protection against pneumococcal infection.
50 accination might be the key to prevention of pneumococcal infection.
51 nd may provide a novel target for preventing pneumococcal infection.
52 riants, each playing a different role during pneumococcal infection.
53 low CD4(+) cell counts have a higher rate of pneumococcal infection.
54 s a key molecule in the host defense against pneumococcal infection.
55 ty, improving clinical outcomes after severe pneumococcal infection.
56 te the role of ATP in neutrophil response to pneumococcal infections.
57 es now represent the best strategy to combat pneumococcal infections.
58 ne candidate for protection against invasive pneumococcal infections.
59 have notable implications for the control of pneumococcal infections.
60  the effectiveness of existing therapies for pneumococcal infections.
61 s part of the protein are protective against pneumococcal infections.
62 nd in populations with a higher incidence of pneumococcal infections.
63 moking and other factors as risk factors for pneumococcal infections.
64 y of a MAb to passively protect mice against pneumococcal infections.
65 ould be an effective strategy for preventing pneumococcal infections.
66  polymorphisms were associated with invasive pneumococcal infections.
67 ease (IBD) are at increased risk of invasive pneumococcal infections.
68 ed, which determined the clinical outcome of pneumococcal infections.
69 ers to intravenous (i.v.) penicillin use for pneumococcal infections.
70 ine antigen test in patients with bacteremic pneumococcal infections.
71 ermine what proportion could be confirmed as pneumococcal infections.
72 -infected patients have an increased rate of pneumococcal infections.
73 e inflammatory profiles are generated during pneumococcal infection, a common pattern emerged, which
74                                              Pneumococcal infections account for a significant propor
75 ent of, and outcomes in, septic shock during pneumococcal infection, acute respiratory distress syndr
76 ction of the protective humoral responses to pneumococcal infection, administration of MR-1 had no ef
77      Stimulation of CCL2 by macrophages upon pneumococcal infection alone required the pattern recogn
78                 To identify risk factors for pneumococcal infection among human immunodeficiency viru
79 59 months were 56 (UR 37-71) per 100 000 for pneumococcal infection and 13 (UR 8-18) per 100 000 for
80 nd reduces bacterial loads during concurrent pneumococcal infection and allergic airway inflammation
81  intravenous, and intranasal routes prior to pneumococcal infection and by aerosol 24 h following inf
82 o role of AM MARCO in innate defense against pneumococcal infection and environmental particles.
83 lay an important role in the pathogenesis of pneumococcal infection and has been identified as a puta
84 S61F is an effective mucosal vaccine against pneumococcal infection and induces CD4+ Th2-type cells,
85 e in eliciting pulmonary inflammation during pneumococcal infection and is required for lethal system
86 that cigarette smoke predisposes to invasive pneumococcal infection and mortality in an animal model.
87 2 receptor subunit alpha-1 (IL-22Ra1) during pneumococcal infection and that Il22ra2(-/-) macrophages
88 is indispensable for innate immunity against pneumococcal infection and that PspA interferes with the
89 f macrophage deactivation for the outcome of pneumococcal infections and highlight the role of LCN2 a
90 t has been shown that CRP protects mice from pneumococcal infection, and an active complement system
91  Cirrhosis is a major risk factor for severe pneumococcal infection, and patients evaluated for liver
92 2) and SO(2)) can increase susceptibility to pneumococcal infection are less well understood.
93                                              Pneumococcal infections are common and serious complicat
94  apoptosis of a variety of brain cells after pneumococcal infection arises from inhibition of PtdCho
95 ndeed, DNA was present in the cytosol during pneumococcal infection as indicated by the activation of
96            Increasing PCV10 coverage reduced pneumococcal infection at all ages, implying at least a
97 ects, this establishes a niche for secondary pneumococcal infection by altering early cellular innate
98 a major contribution in the host response to pneumococcal infection by increasing circulating neutrop
99 /c nor CBA/N mice were protected from lethal pneumococcal infections by immunization with peptide 1-B
100 one macrophages to protect against a primary pneumococcal infection can, under conditions of splenome
101                                              Pneumococcal infections can lead to uncontrolled hyperin
102                                              Pneumococcal infections cause serious illness and death
103 protected HIV-infected adults from recurrent pneumococcal infection caused by vaccine serotypes or se
104 e primary end point was a further episode of pneumococcal infection caused by vaccine serotypes or se
105   Serum from a patient recovering from acute pneumococcal infection contained IgG antibodies specific
106    The rate of antibiotic-resistant invasive pneumococcal infections decreased in young children and
107        Lungs of mice that had recovered from pneumococcal infections did not contain organized tertia
108 her the frequency and character of secondary pneumococcal infections differed depending on the strain
109           Nkrp1b(-/-) mice are vulnerable to pneumococcal infection due to an age-dependent collapse
110 the innate immune defense mechanisms against pneumococcal infection during the early stage of acute O
111 T) are immunocompromised and at high risk of pneumococcal infections, especially in the months follow
112 of antimicrobial agents for the treatment of pneumococcal infections for specific types of infection
113 varicella, and risk of invasive disease from pneumococcal infections have declined.
114 ke daily prophylactic antibiotics to prevent pneumococcal infections; however, how much prophylactic
115                    We used a database of all pneumococcal infections identified at our medical center
116                     Repeated observations of pneumococcal infection in 121 United Kingdom families (O
117 atural viral infection with controlled human pneumococcal infection in 581 healthy adults screened fo
118  well as THP-1 macrophages produced MIF upon pneumococcal infection in a pneumolysin-dependent manner
119 in epidemiological investigation of invasive pneumococcal infection in adults, particularly if combin
120  generally considered a rare complication of pneumococcal infection in adults.
121 PN affects inflammation and vulnerability to pneumococcal infection in atopic asthma.
122 t OPN significantly affects vulnerability to pneumococcal infection in atopic asthma.
123 ding protein were increased (P < 0.05) after pneumococcal infection in both acutely ill and convalesc
124 e present study, we compared the severity of pneumococcal infection in C57BL/6 (B6) and 129Sv mice.
125 nia, which is a more common manifestation of pneumococcal infection in elderly persons.
126 uation and for determining the prevalence of pneumococcal infection in epidemiological studies of com
127 ctor capable of eliciting protection against pneumococcal infection in mice.
128 ining the increased vulnerability to acquire pneumococcal infection in parallel with sustained allerg
129 at there is a significant long-term risk for pneumococcal infection in patients who have undergone al
130  statin therapy might improve the outcome of pneumococcal infection in SCD.
131  an important role in hypersusceptibility to pneumococcal infection in sickle cell disease.
132 rface proteins can protect against secondary pneumococcal infection in the mouse model.
133 IL-22 was rapidly induced in the lung during pneumococcal infection in wild-type mice, and Il22(-/-)
134 d test for the early diagnosis of bacteremic pneumococcal infections in adult patients, even after an
135 aphic assay, for the diagnosis of bacteremic pneumococcal infections in hospitalized adult patients.
136 es to PspA may have some utility in treating pneumococcal infections in humans.
137 D: RSV contributed 1.87% (CI 0.89%-3.08%) to pneumococcal infections in the 65+ group, whereas 2.14%
138 sible for almost 40% of penicillin-resistant pneumococcal infections in the United States in the late
139 ule is effective for preventing vaccine-type pneumococcal infections in young children not infected w
140 at treatment with exogenous sialic acid post-pneumococcal infection increased the numbers of CFU reco
141 umoniae The incidence and mortality rate for pneumococcal infection increases dramatically after age
142 tablished lung fibrosis completely inhibited pneumococcal infection-induced fibrosis exacerbation as
143  fibrosis and further increased in mice with pneumococcal infection-induced lung fibrosis exacerbatio
144                                     Invasive pneumococcal infection (IPI) is the most common serious
145                                     Although pneumococcal infection is a serious problem worldwide an
146 at the extent of protection against systemic pneumococcal infection is influenced by target antigen a
147 the protective capacity of serum IgM against pneumococcal infection is maintained in IgM obtained fro
148                    Inflammation triggered by pneumococcal infection is necessary for bacterial cleara
149                      The diagnosis of severe pneumococcal infections is inadequate, relying heavily o
150 uction during concurrent influenza virus and pneumococcal infection leads to increased bacterial colo
151 mechanisms whereby pIgA may serve to control pneumococcal infections locally and upon the pathogen's
152 ity that cardiac scar formation after severe pneumococcal infection may explain why individuals who a
153 vaccination for protection against secondary pneumococcal infection, mice were immunized with pneumoc
154 ogens, whereas seasonality of other invasive pneumococcal infections might be primarily driven by inc
155                In order to monitor long-term pneumococcal infections noninvasively in living mice, a
156  role of microRNAs (miRNAs) as regulators in pneumococcal infection of human macrophages.
157 pe were found to have significant effects on pneumococcal infection of the nasopharynx, trachea, and
158                                              Pneumococcal infection of the respiratory tract is often
159                                              Pneumococcal infection often follows a primary viral inf
160 f asthma on the subsequent susceptibility to pneumococcal infection, ovalbumin (OVA)-induced allergic
161  of vaccine efficacy after dose 3 leading to pneumococcal infection), PCV13 and PPSV23 (Guillain-Barr
162 ear to have been selected for in vivo during pneumococcal infection, perhaps as a consequence of immu
163 ve inadequate antibiotic prophylaxis against pneumococcal infections, placing them at increased risk
164                 Finally, in a mouse model of pneumococcal infection, pneumolysin-producing pneumococc
165 itive rechallenges, and 34 cases of invasive pneumococcal infections possibly representing vaccine fa
166                In a mouse model of secondary pneumococcal infection, protection mediated by mAb PhtD3
167                In a murine model of invasive pneumococcal infection, PTX3 was strongly induced in non
168                                              Pneumococcal infections remain a leading cause of death
169                                              Pneumococcal infections remain a leading cause of death
170                                              Pneumococcal infections remain the most important cause
171 other than the V1 H chain to protect against pneumococcal infection remains controversial.
172  to a 400-fold greater incidence of invasive pneumococcal infection resulting in fulminant, lethal pn
173                                              Pneumococcal infection risk and contact behaviour were h
174 es and failed to effectively clear pulmonary pneumococcal infection, showing that immunodeficiency re
175                   HbSS mice developed severe pneumococcal infection significantly faster than C57BL/6
176 fer non-serotype-specific protection against pneumococcal infections such as pneumonia, meningitis, a
177 ith littermate controls after intrapulmonary pneumococcal infection, suggesting that IL-22 signaling
178 9Sv mice were remarkably more susceptible to pneumococcal infection than B6 mice.
179      Here, we demonstrate in mouse models of pneumococcal infection that Har is critical for coloniza
180 nnate immune recognition pathway that senses pneumococcal infection, triggers type I IFN production,
181 ore, they should be partly protected against pneumococcal infection until month 15.
182 like receptor 4 (TLR4) confers resistance to pneumococcal infection via its interaction with pneumoly
183 , pulmonary innate defense against secondary pneumococcal infection was severely suppressed.
184 though a substantial proportion of recurrent pneumococcal infections was potentially preventable by v
185 er DAS181 would lead to an increased risk of pneumococcal infection, we tested S. pneumoniae coloniza
186          Risk profiles and manifestations of pneumococcal infection were ascertained from diagnosis,
187 er 1998, 14.9% (404/2717) of those who had a pneumococcal infection were HIV infected.
188 d control patients with penicillin-sensitive pneumococcal infections were compared.
189 eads to enhanced susceptibility to secondary pneumococcal infection, which can be prevented by IFN-ga
190 e phagocytosis during innate defense against pneumococcal infection, which may explain the associatio
191 tanding of molecular and cellular biology of pneumococcal infection will allow the development of new
192 usion protein was broadly protective against pneumococcal infection, with the potential for additiona
193 inary antigen testing (UAT) when identifying pneumococcal infection would allow for antibiotic de-esc
194 inary antigen testing (UAT) when identifying pneumococcal infection would allow for antibiotic de-esc

 
Page Top